The breast cancer subtyping kits market is projected to grow from USD 4.8 billion in 2026 to USD 12.0 billion by 2036, at a CAGR of 9.6%. IHC-based kits will dominate with a 46.0% market share, while her2 subtyping will lead the application segment with a 38.0% share.